A Safety Surveillance Study of Events of Special Interest Occurring in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
- Indications Macular degeneration
- Focus Adverse reactions
- Sponsors Astellas Institute for Regenerative Medicine
- 06 Feb 2018 Planned number of patients changed from 37 to 36.
- 06 Feb 2018 Status changed from not yet recruiting to recruiting.
- 12 Dec 2017 Planned initiation date changed from 1 Oct 2017 to 1 Dec 2017.